KRAS: feeding pancreatic cancer proliferation: Trends in Biochemical Sciences
Mutant KRAS is continuously in a GTP‐bound, active state. Wild‐type... | Download Scientific Diagram
Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine | Nature Communications
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer | Nature Reviews Gastroenterology & Hepatology
Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling | PLOS Computational Biology
The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience | Cancer Genomics & Proteomics
Immune modulatory effects of oncogenic KRAS in cancer | Nature Communications
Targeting KRAS mutant cancers: from druggable therapy to drug resistance | Molecular Cancer | Full Text
KRAS: feeding pancreatic cancer proliferation: Trends in Biochemical Sciences
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Cancers | Free Full-Text | Synthetic Vulnerabilities in the KRAS Pathway
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism: Cell
Acquired Resistance to KRASG12C Inhibition in Cancer | NEJM
KRAS oncogene in lung cancer: focus on molecularly driven clinical trials | European Respiratory Society
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer - eBioMedicine
Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein | PNAS
KRAS G12V Protein, Human, Recombinant, Biotinylated – Amid Biosciences | Protein Engineering Company
Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors | Anticancer Research
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge | Cell Discovery
A systems mechanism for KRAS mutant allele–specific responses to targeted therapy | Science Signaling
KRAS mutated Non‐Small Lung Carcinoma: A Real World Context from the Indian subcontinent - Batra - 2023 - Cancer Medicine - Wiley Online Library
